GlassScriptPhysician profile
Alan Alexander Semion
NPI 1235131301
$3,187.57
in general payments reported to CMS, 2019-2025
23 companies · $153 in 2025
The $153 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $312 · 2021: $599 · 2022: $616 · 2023: $337 · 2024: $238 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.65 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $623.50 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $430.41 | 2021-2025 | Tremfya |
| Genentech USA, INC. | $360.06 | 2019-2022 | |
| Lilly USA, LLC | $204.31 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $201.08 | 2019-2021 | |
| Amgen INC. | $200.50 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $181.19 | 2019-2022 | |
| Dusa Pharmaceuticals, INC. | $143.15 | 2019 | |
| Arcutis Biotherapeutics, INC. | $122.31 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $101.04 | 2021-2024 | Sotyktu |
| Ucb, INC. | $85.55 | 2022 | |
| Leo Pharma INC. | $76.47 | 2021-2022 | |
| Galderma Laboratories, L.P. | $68.79 | 2019-2024 | |
| Merz North America, INC. | $67.98 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $63.35 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $58.14 | 2022 | |
| Biofrontera INC. | $48.58 | 2019-2024 | Ameluz, Rhodoled Xl, Xepi |
| Genzyme Corporation | $38.82 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $36.03 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.99 | 2023 | Spevigo |
| Merck Sharp & Dohme LLC | $19.47 | 2019 | |
| Pfizer INC. | $17.40 | 2023 | |
| Incyte Corporation | $15.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Semion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.